{"nctId":"NCT00699348","briefTitle":"A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia","startDateStruct":{"date":"2008-07"},"conditions":["Anemia"],"count":351,"armGroups":[{"label":"C.E.R.A.","type":"EXPERIMENTAL","interventionNames":["Drug: Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)"]}],"interventions":[{"name":"Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)","otherNames":["Mircera"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic renal anemia;\n* Continuous intravenous maintenance erythropoietin stimulating agent (ESA) treatment during previous month;\n* Regular long term hemodialysis therapy with the same mode of dialysis for \\>=3 months.\n\nExclusion Criteria:\n\n* Transfusion of red blood cells during previous 2 months;\n* Significant acute or chronic bleeding, such as overt gastrointestinal bleeding;\n* Active malignant disease (except non-melanoma skin cancer).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Maintaining Mean Hemoglobin Concentration Within Plus or Minus (+/-) 1 Gram Per Deciliter (g/dL) of Reference and Within the Target Range","description":"Percentage of participants maintaining the mean hemoglobin concentration within +/- 1.0 g/dL of their reference hemoglobin value and within the target range of 10.0 to 12.0 g/dL during the efficacy evaluation period (EEP) was assessed. The reference hemoglobin value was defined on the basis of the 5 assessments recorded during the stability verification period (SVP) at Weeks -4, -3, -2, -1 and 0. The mean hemoglobin concentration for each individual participant during the EEP (Week 17 to Week 24) was estimated as a time adjusted average.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hemoglobin Concentration Between Reference SVP and EEP","description":"The mean change of the time adjusted average of hemoglobin from reference value obtained during the SVP (Week -4 up to Week 0) and the value during EEP (Week 17 up to Week 24) was assessed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.98"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Maintaining Hemoglobin Concentration Within the Target Range","description":"Percentage of participants maintaining hemoglobin concentration within the target range of 10.0 to 12.0 g/dL during EEP (Week 17 to Week 24) was assessed.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Time Spent by Participants With Hemoglobin Concentration in the Target Range During the EEP","description":"Median time spent by participants with hemoglobin concentration within the target range of 10.0 to 12.0 g/dL during the EEP (Week 17 to Week 24) was assessed.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring Any Dose Adjustment","description":"Percentage of participants requiring any adjustment in the dose of study drug during the dose titration period (DTP: Week 1 to Week 16) and EEP (Week 17 to Week 24) was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Red Blood Cell Transfusion During the Study","description":"Number of participant who underwent red blood cell transfusion during the study was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":98,"n":351},"commonTop":["Hypertension"]}}}